Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy

Abstract

Objective:

To report 3 successful treatments of vancomycin-resistant Enterococcus faecium meningitis in adults using daptomycin and either linezolid or gentamicin.

Case Summary:

Three case reports involving males (aged 58-78 years) are presented; in each case (trigeminal nerve microvascular decompression and subdural hygroma; paraspinal abscess; and hydrocephalus with subsequent craniotomy and ventriculo-peritoneal shunt placement) CSF examination revealed vancomycin-resistant Enterococcus (VRE) susceptible to daptomycin, gentamicin, and/or linezolid. Three- to four-week treatment regimens with daptomycin 6-12 mg/kg and either gentamicin or linezolid led to clinical resolution and microbiological clearance of infection.

Discussion:

Daptomycin has previously been shown to be successful in treating methicillin-resistant Staphylococcus aureus–associated meningitis and other serious VRE and enterococcal infections. Higher than approved doses of daptomycin were used in 2 cases where in theory higher CSF concentrations would thus be obtained. Gentamicin and linezolid were added to daptomycin therapy based on in vitro data synergy results and because of documented successful treatment for VRE meningitis, respectively.

Conclusions:

The difficulty in treating VRE CSF infections involves both drug kinetics and microbial resistance factors, as well as external factors such as foreign bodies like shunts. This report highlighted 3 cases where daptomycin use in concert with either gentamicin or linezolid was successful in treating this infection. Additional controlled trials will be helpful in identifying the best strategies when using daptomycin to treat CSF infections.

Keywords

cerebrospinal fluid shunt infections daptomycin meningitis vancomycin-resistant Enterococcus

Get full access to this article

View all access options for this article.

References

Tunkel

, Drake

. Cerebrospinal fluid shunt infections. In: Mandell

, Bennett

, Dolin

, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier, Inc., 2010: 1231–6.

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470–85. DOI 10.1016/S0196655304005425

Hidron

, Edwards

, Patel

. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996–1011. DOI 10.1086/591861

Lee

, Palermo

, Chowdhury

. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588–90. DOI 10.1086/590257

Jenkins

. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007; 2:343–4. DOI 10.1002/jhm.236

Gallagher

, Perez

, Marino

, LoCastro

, Abrardo

, MacDougall

. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009; 29:792–9. DOI 10.1592/phco.29.7.792

Elvy

, Porter

, Brown

. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008; 61:461–2. DOI 10.1093/jac/dkm501

Jaspan

, Brothers

, Campbell

. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2009; 29:379–81. DOI 10.1097/INF.0b013e3181c806d8

Allen

, Cha

, Rybak

. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46:2606–12.

10.

Bain

, Wittbrodt

. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001; 35:566–75. DOI 10.1345/aph.10276

11.

Caron

, Kitzis

, Gutmann

. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36: 2611–6.

12.

Cilli

, Aydemir

, Tunger

. In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006; 18:27–32.

13.

Eliopoulos

, Wennersten

. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002; 46:1319–24.

14.

Gill

, Murphy

, Hamer

. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect 2002; 45:129–32. DOI S0163445302909795

15.

Kang

, Rybak

. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39(suppl A):33–9.

16.

Matsumura

, Louie

, Simor

. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999; 43:2776–9.

17.

Mercier

, Kennedy

, Meadows

. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22:1517–23.

18.

Messick

, Rodvold

, Pendland

. Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations. J Antimicrob Chemother 1999; 44:831–4.

19.

Pankey

, Ashcraft

, Patel

. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49:5166–8. DOI 10.1128/AAC.49.12.5166-5168.2005

20.

Patel

, Rouse

, Piper

, Steckelberg

. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38: 177–9. DOI S0732-8893(00)00193-0

21.

Saravolatz

, Stein

, Johnson

. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908–14. DOI 10.1086/648438

22.

Miranda

, Tunkel

. Strategies and new developments in the management of bacterial meningitis. Infect Dis Clin North Am 2009; 23:925–43, viii-ix. DOI 10.1016/j.idc.2009.06.014

23.

Rose

, Rybak

, Kaatz

. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60:334–40. DOI 10.1093/jac/dkm170

24.

Rose

, Leonard

, Rybak

. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52:3061–7. DOI 10.1128/AAC.00102-08

25.

Cotroneo

, Harris

, Perlmutter

, Beveridge

, Silverman

. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2223–5. DOI 10.1128/AAC.01410-07

26.

Stucki

, Cottagnoud

, Winkelmann

, Schaffner

, Cottagnoud

. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother 2007; 51:2249–52. DOI 10.1128/AAC.01000-06

27.

Cottagnoud

, Pfister

, Acosta

. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928–33. DOI 10.1128/AAC.48.103928-3933.2004

28.

Grandgirard

, Oberson

, Buhlmann

, Gaumann

, Leib

. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010; 54:1323–6. DOI 10.1128/AAC.00812-09

29.

Gerber

, Stucki

, Acosta

, Cottagnoud

. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57:720–3. DOI 10.1093/jac/dk1007

30.

Egermann

, Stanga

, Ramin

. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009; 53:3030–3. DOI 10.1128/AAC.00952-08

31.

Riser

, Bland

, Rudisill

, Bookstaver

. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann Pharmacother 2010; 44:1832–5. DOI 10.1345/aph.1P307

32.

Alou

, Aguilar

, Gimenez

, Torrico

, Sevillano

. Activity of serum concentrations of daptomycin vs vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation. Eur J Clin Microbiol Infect Dis 2008; 27:1009–11. DOI 10.1007/s10096-008-0525-3

33.

Moise

, Hershberger

, Amodio-Groton

, Lamp

. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43:1211–9. DOI 10.1345/aph.1M085

34.

Figueroa

, Mangini

, Amodio-Groton

. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177–80. DOI 10.1086/600039

35.

Benvenuto

, Benziger

, Yankelev

, Vigliani

. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245–9. DOI 10.1128/AAC.00247-06

36.

Wise

, Gee

, Andrews

, Dvorchik

, Marshall

. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46:31–3.

37.

LaPlante

, Rybak

. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665–72. DOI 10.1128/AAC.48.12.4665-4672.2004

38.

Gavalda

, Cardona

, Almirante

. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob Agents Chemother 1996; 40:173–8.

39.

Gavalda

, Onrubia

, Gomez

. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52:514–7. DOI 10.1093/jac/dkg360

40.

Graham

, Ampofo

, Saiman

. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21:798–800.

41.

Shaikh

, Peloquin

, Ericsson

. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001; 33:375–9.

42.

Steinmetz

, Vogelbaum

, De Georgia

, Andrefsky

, Isada

. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001; 29:2383–5.

43.

Tsai

, Wu

, Peng

, Giian

, Lee

, Lu

. Short course of linezolid treatment for vancomycin-resistant Enterococcus faecium meningitis. Int J Clin Pract 2006; 60:740–1. DOI 10.1111/j.1368-5031.2006.00706.x

44.

Zeana

, Kubin

, Della-Latta

, Hammer

. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477–82. DOI 10.1086/321896

45.

Webster

, Griffiths

, Bowler

. Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium. J Antimicrob Chemother 2009; 63: 622–3. DOI 10.1093/jac/dkn519

46.

Seedat

, Zick

, Klare

, Konstabel

, Weiler

, Sahly

. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006; 50:4217–9. DOI 10.1128/AAC.00518-06

47.

Swoboda

, Fritz

, Martignoni

. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005; 56:787–9. DOI 10.1093/jac/dki318

48.

Sakoulas

, Moise

, Nizet

. Ampicillin enhances the activity of daptomycin by alteration of surface charge in vancomycin-resistant Enterococcus faecium. Abstract E-806.49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12, 2009, San Francisco, CA.

49.

Entenza

, Giddey

, Vouillamoz

, Moreillon

. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int J Antimicrob Agents 2010; 35:451–6. DOI 10.1016/j.ijantimicag.2009.12.022

50.

Garrison

, Mutters

, Dowzicky

. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009; 65:288–99. DOI 10.1016/j.diagmicrobio.2009.07.010

51.

Abb

. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium. Int J Antimicrob Agents 2007; 29: 358–60. DOI 10.1016/j.ijantimicag.2006.10.007

52.

Moise

, Castro

, Sul

, Forrest

, Sakoulas

. Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection (letter). Ann Pharmacother 2008; 42:592–3. DOI 10.1345/aph.1K613

53.

Jorgensen

, Crawford

, Kelly

, Patterson

. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003; 47:3760–3.